The FDA’s efficacy evaluation included 67 patients previously treated with alectinib as their only ALK TKI in the metastatic setting and 155 patients previously treated with at least 2 ALK TKIs and platinum-based chemotherapy. Confirmed overall response rate (ORR) and duration of response (DOR) were assessed by blinded independent central review using RECIST version 1.1.¹
In the prior-alectinib group, ORR was 49% (95% CI, 37%-62%). Among responding patients, 76% had a DOR of at least 6 months and 52% had a DOR of at least 12 months.1
In the more heavily pretreated group, ORR was 32% (95% CI, 24%-40%). Among responders, 69% had a DOR of at least 6 months and 51% had a DOR of at least 12 months. These durability percentages describe responding patients rather than all patients in each efficacy population.1
Because ALKOVE-1 was single-arm, the reported results do not establish an efficacy advantage over another ALK inhibitor or chemotherapy. The differing treatment histories also limit direct comparisons between the 2 groups.1
Dosing and Safety Considerations for Pharmacists
The recommended dose is 150 mg orally once daily, taken at the same time each day with or without food. Treatment continues until disease progression or unacceptable toxicity.1
Warnings and precautions include hepatotoxicity, renal toxicity, ocular toxicity, creatine phosphokinase elevation, and embryo-fetal toxicity. Adverse reactions occurring in at least 20% of patients included hepatotoxicity and musculoskeletal pain, along with constipation, dysgeusia, peripheral neuropathy, edema, and fatigue.1
These risks give pharmacists several priorities when preparing patients for therapy. Counseling can reinforce consistent daily administration and encourage early reporting of vision changes or worsening muscle symptoms. Patients should also understand that new or worsening neuropathy, constipation, or swelling warrants discussion with the oncology team. The embryo-fetal toxicity warning makes reproductive counseling another component of treatment preparation.1
Medication reconciliation and an individualized monitoring plan should accompany initiation. Pharmacists should consult the full prescribing information for laboratory monitoring schedules, interaction management, and dose modifications as it becomes available through Drugs@FDA.1
Accelerated Approval Requires Confirmation of Benefit
The decision was based on tumor response and response durability. Under the FDA’s accelerated approval pathway, additional studies are required to confirm anticipated clinical benefit; response findings alone do not demonstrate longer survival.1,4
The application received priority review, and neladalkib previously received breakthrough therapy and orphan drug designations. For eligible patients, the approval adds another treatment option after the prior regimens specified in the indication.1
